Product
HER2-primed Dendritic cells
1 clinical trial
2 indications
Indication
Triple-Negative Breast CancerIndication
Breast CancerClinical trial
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)Status: Recruiting, Estimated PCD: 2024-06-01